John L Neumeyer

List of Publications by Year
in descending order

61 papers	2,248 citations	218677 26 h-index	214800 47 g-index
64 all docs	64 docs citations	64 times ranked	1792 citing authors

#	Article	IF	Citations
1	Recent Progress in Development of Dopamine Receptor Subtype-Selective Agents:Â Potential Therapeutics for Neurological and Psychiatric Disorders. Chemical Reviews, 2007, 107, 274-302.	47.7	344
2	[123I]-2.beta.-carbomethoxy-3.beta.-(4-iodophenyl)tropane: high-affinity SPECT (single photon emission) Tj ETQq0 0 0 rgBT /Overlock 1 Chemistry, 1991, 34, 3144-3146.	6.4	264
3	N-.omega.-Fluoroalkyl Analogs of (1R)-2.beta.-Carbomethoxy-3.beta.-(4-iodophenyl)tropane (.beta.-CIT): Radiotracers for Positron Emission Tomography and Single Photon Emission Computed Tomography Imaging of Dopamine Transporters. Journal of Medicinal Chemistry, 1994, 37, 1558-1561.	6.4	149
4	Advances in Development of Dopaminergic Aporphinoids. Journal of Medicinal Chemistry, 2007, 50, 171-181.	6.4	103
5	A preliminary PET evaluation of the new dopamine D2 receptor agonist [11C]MNPA in cynomolgus monkey. Nuclear Medicine and Biology, 2005, 32, 353-360.	0.6	91
6	Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines. European Journal of Pharmacology, 2003, 474, 137-140.	3.5	85
7	Design and Synthesis of Novel Dimeric Morphinan Ligands for Îº and Î¼ Opioid Receptors. Journal of Medicinal Chemistry, 2003, 46, 5162-5170.	6.4	75
8	Effects of Mixed-Action Îº/Î¼ Opioids on Cocaine Self-Administration and Cocaine Discrimination by Rhesus Monkeys. Neuropsychopharmacology, 2003, 28, 1125-1139.	5.4	65
9	Synthesis and dopamine receptor affinities of enantiomers of 2-substituted apomorphines and their N-n-propyl analogs. Journal of Medicinal Chemistry, 1990, 33, 1800-1805.	6.4	61
10	Synthesis and Opioid Receptor Affinity of Morphinan and Benzomorphan Derivatives:Â Mixed Îº Agonists and Î¼ Agonists/Antagonists as Potential Pharmacotherapeutics for Cocaine Dependenceâ€. Journal of Medicinal Chemistry, 2000, 43, 114-122.	6.4	61
11	Aporphines. 8. Total Synthesis and Pharmacological Evaluation of (Â±)-Apomorphine, (Â±)-Apocodeine, (Â±)-N-n-Propylnorapomorphine, and (Â±)-N-n-Propylnorapocodeine. Journal of Medicinal Chemistry, 1973, 16, 1223-1228.	6.4	55
12	Long-Term Effects of S(+)N-n-Propylnorapomorphine Compared with Typical and Atypical Antipsychotics: Differential Increases of Cerebrocortical D2-Like and Striatolimbic D4-Like Dopamine Receptors. Neuropsychopharmacology, 1997, 17, 186-196.	5.4	53
13	Synthesis and Preliminary In vitro Investigation of Bivalent Ligands Containing Homo- and Heterodimeric Pharmacophores at Î¼, Î´, and Îº Opioid Receptors. Journal of Medicinal Chemistry, 2006, 49, 256-262.	6.4	47
14	Chemistry and Pharmacology of Marijuana. Journal of Pharmaceutical Sciences, 1971, 60, 1433-1457.	3.3	45
15	S-(+)-aporphines are not selective for human D3 dopamine receptors. Cellular and Molecular Neurobiology, 1994, 14, 185-191.	3.3	44
16	Stereoisomeric probes for the D1 dopamine receptor: synthesis and characterization of R-(+) and S-(-) enantiomers of 3-allyl-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine and its 6-bromo analog. Journal of Medicinal Chemistry, 1992, 35, 1466-1471.	6.4	42
17	Synthesis and dopamine receptor affinity of (R)-(-)-2-fluoro-N-n-propylnorapomorphine: a highly potent and selective dopamine D2 agonist. Journal of Medicinal Chemistry, 1990, 33, 3122-3124.	6.4	40
18	Isomeric selectivity at dopamine D3 receptors. European Journal of Pharmacology, 1993, 239, 269-270.	3.5	37

#	Article	IF	Citations
19	Synthesis of 2-Fluoro-11-hydroxy-N-propylnoraporphine:â€‰ A Potential Dopamine D2Agonist. Organic Letters, 2005, 7, 3239-3242.	4.6	31
20	Synthesis and neuropharmacological evaluation of R(â˜')-N-alkyl-11-hydroxynoraporphines and their esters. Bioorganic and Medicinal Chemistry, 2004, 12, 3553-3559.	3.0	30
21	Synthesis and Dopamine Receptor Affinities of N-Alkyl-11-hydroxy-2-methoxynoraporphines: N-Alkyl Substituents Determine D1 versus D2 Receptor Selectivity. Journal of Medicinal Chemistry, 2008, 51, 983-987.	6.4	30
22	Synthesis and Opioid Receptor Binding Affinities of 2-Substituted and 3-Aminomorphinans: Ligands for Î¼, Îº, and Î´ Opioid Receptors. Journal of Medicinal Chemistry, 2010, 53, 402-418.	6.4	30
23	Aporphines. 48. Enantioselectivity of (R)-(-)- and (S)-(+)-N-n-propylnorapomorphine on dopamine receptors. Journal of Medicinal Chemistry, 1983, 26, 516-521.	6.4	29
24	New Opioid Designed Multiple Ligand from Dmt-Tic and Morphinan Pharmacophores. Journal of Medicinal Chemistry, 2006, 49, 5640-5643.	6.4	29
25	2-Haloaporphines as potent dopamine agonists. Journal of Medicinal Chemistry, 1989, 32, 1198-1201.	6.4	28
26	(.+-.)-3-Allyl-6-bromo-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine, a new high affinity D1 dopamine receptor ligand: synthesis and structure-activity relationship. Journal of Medicinal Chemistry, 1991, 34, 3366-3371.	6.4	28
27	Selective antidopaminergic effects of S(+)N-n-propylnoraporphines in limbic versus extrapyramidal sites in rat brain: comparisons with typical and atypical antipsychotic agents. Psychopharmacology, 1991, 103, 323-329.	3.1	27
28	Kappa opioid agonists as targets for pharmacotherapies in cocaine abuse. Pharmaceutica Acta Helvetiae, 2000, 74, 337-344.	1.2	23
29	¹⁸F-MCL-524, an ¹⁸F-Labeled Dopamine D₂ and D₃ Receptor Agonist Sensitive to Dopamine: A Preliminary PET Study. Journal of Nuclear Medicine, 2014, 55, 1164-1170.	5.0	20
30	Synthesis and dopamine receptor binding of sulfur-containing aporphines. Bioorganic and Medicinal Chemistry, 2006, 14, 1918-1923.	3.0	19
31	Synthesis of Î²-CIT-BAT, a potential technetium-99m imaging ligand for dopamine transporter. Tetrahedron Letters, 1996, 37, 4353-4356.	1.4	18
32	Chemistry of aporphines. IV. Synthesis of aporphines via Reissert alkylation, photochemical cyclization, and the Pschorr cyclization route. Journal of Organic Chemistry, 1969, 34, 3786-3788.	3.2	16
33	Synthesis of aminothiazole derived morphinans. Tetrahedron Letters, 2003, 44, 6459-6462.	1.4	16
34	Synthesis and binding studies of 2-O- and 11-O-substituted N-alkylnoraporphines. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 3971-3973.	2.2	16
35	Preliminary Pharmacological Evaluation of Enantiomeric Morphinans. ACS Chemical Neuroscience, 2014, 5, 93-99.	3.5	16
36	Altered spontaneous behavior and sensitivity to apomorphine in rats following pretreatment with S(+)-aporphines or fluphenazine. Psychopharmacology, 1993, 111, 351-358.	3.1	15

#	Article	IF	Citations
37	Synthesis and Pharmacological Evaluation of Aminothiazolomorphinans at the Mu and Kappa Opioid Receptors. Journal of Medicinal Chemistry, 2013, 56, 8872-8878.	6.4	15
38	An investigation of the N-demethylation of 3-deoxymorphine and the affinity of the alkylation products to Î¼, Î´, and Îº receptors. Bioorganic and Medicinal Chemistry, 2004, 12, 2687-2690.	3.0	14
39	Synthesis and Evaluation of Fluorinated Aporphines: Potential Positron Emission Tomography Ligands for D₂ Receptors. ACS Medicinal Chemistry Letters, 2011, 2, 189-194.	2.8	14
40	Synthesis of aporphines. Tetrahedron Letters, 1967, 8, 3107-3109.	1.4	12
41	Synthesis, Binding Affinity, and Functional in Vitro Activity of 3-Benzylaminomorphinan and 3-Benzylaminomorphine Ligands at Opioid Receptors. Journal of Medicinal Chemistry, 2012, 55, 3878-3890.	6.4	9
42	Facile Synthesis of Isoindoline and Substituted Isoindolines. Journal of Pharmaceutical Sciences, 1964, 53, 981-982.	3.3	8
43	Aporphines 24. The synthesis of Nâ€alkylderivatives of bulbocapnine and isoeorydine. Journal of Heterocyclic Chemistry, 1979, 16, 87-92.	2.6	7
44	Aporphines 65: Chemical, microbial synthesis and characterization by gas chromatography/mass spectrometry of (R)-(â^')-10-hydroxy 11-methoxy-N-n-propylnoraporphine, a potential metabolite ofN-n-propylnorapomorphine. Biological Mass Spectrometry, 1986, 13, 223-229.	0.5	7
45	N-Phthalimidoalkyl derivatives of 2Î²-carbomethoxy-3Î²-(4â€²-iodophenyl)tropane (Î²-CIT): Brain monoamine transporter affinity. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 337-340.	2.2	7
46	Oral r-(-)-11-o-valeryl-n-n-propylnoraporphine reverses motor deficits in mptp-treated marmosets. Movement Disorders, 2016, 31, 1381-1388.	3.9	7
47	Identification of fluorinated (R)-(â^')-aporphine derivatives as potent and selective ligands at serotonin 5-HT2C receptor. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 230-233.	2.2	7
48	Sulfenylation and Halogenation of Di-and Trianions Derived from Substituted Glutarimides. Synthetic Communications, 1977, 7, 367-374.	2.1	6
49	An efficient synthesis of m-hydroxycocaine and m-hydroxybenzoylecgonine, two metabolites of cocaine. Tetrahedron Letters, 1995, 36, 5861-5864.	1.4	6
50	Convenient Synthesis of N,N,Nâ€²-Trisubstituted Formamidines. Journal of Pharmaceutical Sciences, 1964, 53, 1539-1540.	3.3	5
51	The synthesis of multiple deuterated N-n-propyl-norapomorphine N-(d7) and derivatives. Journal of Labelled Compounds and Radiopharmaceuticals, 1988, 25, 293-299.	1.0	5
52	Convenient synthesis of ¹⁸Fâ€radiolabeled		

#	Article	IF	Citations
55	New Dopamine D2 Receptor Agonist, [3H]MCL-536, for Detecting Dopamine D2high Receptors in Vivo. ACS Chemical Neuroscience, 2018, 9, 1283-1289.	3.5	4
56	Evaluation of Chemical Tests on Vouchered Specimens ofCannabis. Journal of Psychoactive Drugs, 1988, 20, 459-462.	1.7	2
57	Synthesis of potential metabolites of the brain imaging agents methyl (1R,2S,3S,5S)-3-(4-Iodophenyl)-8-alkyl-8-azabicyclo[3.2.1]octane-2-carboxylate. Journal of Heterocyclic Chemistry, 1997, 34, 1633-1636.	2.6	2
58	The High Affinity Dopamine D2 Receptor Agonist MCL-536: A New Tool for Studying Dopaminergic Contribution to Neurological Disorders. ACS Chemical Neuroscience, 2021, 12, 1428-1437.	3.5	2
59	The Non-Anhydrous, Minimally Basic Synthesis of the Dopamine D2 Agonist [18F]MCL-524. Chemistry, 2021, 3, 1047-1056.	2.2	2
60	S(+)-N-n-propylnorapomorphine ([+]-NPA): A novel atypical antipsy chotic with clozapine-like effects. Schizophrenia Research, 1997, 24, 82.	2.0	1
61	Review of Organic Functional Groups. Introduction to Medicinal Chemistry. Journal of Clinical Psychopharmacology, 1984, 4, 240.	1.4	0